ZYME Zymeworks Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1937653 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY97.8%
TTM net income YoY168.3%
TTM EPS YoY162.4%
Revenue 3-yr CAGR-16.8%
Net income 3-yr CAGR-40.5%
Margins
Gross margin—
Operating margin16.6%
Net margin16.3%
FCF margin-42.4%
EBITDA margin18.0%
Returns
ROE15.0%
ROA5.5%
ROIC (approx.)11.7%
Asset turnover0.34x
Leverage & solvency
Liabilities / assets78.0%
Debt / equity1.31x
Current ratio3.30x
Interest coverage—
Cash quality & payout
Operating cash flow / net income-2.59x
Accruals ratio19.7%
Payout ratio—
Capex / revenue0.3%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $256.46M | $4.59M | $2.41M | $2.52M | $27.61M | $48.73M | $27.11M | $31.03M |
| R&D expense | $36.13M | $27.43M | $34.46M | $31.23M | $35.58M | $34.45M | $35.74M | $37.06M |
| SG&A expense | $42.74M | $19.34M | $15.07M | $15.43M | $14.15M | $14.95M | $16.98M | $16.18M |
| Operating income | $177.60M | -$42.18M | -$47.12M | -$44.15M | -$22.11M | -$674,000 | -$25.61M | -$22.22M |
| Pretax income | $173.25M | -$45.29M | -$46.35M | -$41.48M | -$18.27M | $2.13M | -$22.14M | -$17.79M |
| Income tax | -$452,000 | -$273,000 | -$2.19M | -$270,000 | $1.34M | -$186,000 | $496,000 | $5.71M |
| Net income | $173.70M | -$45.02M | -$44.16M | -$41.21M | -$19.60M | $2.32M | -$22.64M | -$23.51M |
| EBITDA | $178.54M | -$41.22M | -$46.16M | -$43.25M | -$21.20M | $211,000 | -$24.63M | -$21.22M |
| EPS (basic) | 2.43 | -0.62 | -0.59 | — | -0.26 | 0.03 | -0.30 | — |
| EPS (diluted) | 2.28 | -0.62 | -0.59 | — | -0.26 | 0.03 | -0.30 | — |
| Weighted avg. shares (diluted) | 76.25M | 72.99M | 74.69M | — | 75.78M | 77.38M | 75.23M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $100.46M | $179.41M | $244.28M | $41.16M | $64.83M | $98.25M | $76.20M | $66.10M |
| Receivables | $413.86M | $5.93M | $4.67M | $4.64M | $29.35M | $2.63M | $24.59M | $55.81M |
| Current assets | $532.40M | $298.39M | $385.68M | $248.77M | $291.71M | $296.13M | $306.47M | $300.45M |
| PP&E, net | $17.91M | $13.96M | $14.85M | $15.50M | $15.82M | $16.31M | $16.68M | $17.65M |
| Goodwill | $116.40M | $12.02M | $12.02M | $12.02M | $12.02M | $12.02M | $12.02M | $12.02M |
| Intangibles | $823,000 | $998,000 | $1.17M | $1.35M | $1.40M | $2.04M | $3.36M | $4.58M |
| Total assets | $1.18B | $396.96M | $478.21M | $346.53M | $397.27M | $408.38M | $425.52M | $463.09M |
| Current liabilities | $161.46M | $47.24M | $35.65M | $42.32M | $42.04M | $38.50M | $65.10M | $88.29M |
| Long-term debt | $338.95M | — | — | — | — | — | — | — |
| Total debt | $338.95M | — | — | — | — | — | — | — |
| Total liabilities | $918.16M | $316.60M | $314.63M | $78.03M | $77.20M | $73.88M | $100.56M | $124.32M |
| Shareholders' equity | $258.25M | $80.37M | $163.59M | $268.50M | $320.06M | $334.51M | $324.97M | $338.77M |
| Net debt | $238.48M | — | — | — | — | — | — | — |
| Shares outstanding | 71.18M | 71.41M | 73.10M | 74.64M | 75.14M | 74.85M | 69.58M | 68.96M |
| Cash flow statement | ||||||||
| Operating cash flow | -$24.04M | -$31.95M | -$45.72M | -$10.26M | -$31.41M | $12.07M | -$3.41M | -$41.51M |
| Capital expenditure | $73,000 | $0 | $216,000 | $581,000 | $410,000 | $514,000 | $16,000 | $314,000 |
| Free cash flow | -$24.11M | -$31.95M | -$45.93M | -$10.84M | -$31.82M | $11.56M | -$3.42M | -$41.82M |
| Investing cash flow | -$389.77M | $17.07M | $69.96M | $5.37M | $368,000 | $8.74M | $12.18M | -$6.21M |
| Financing cash flow | $334.85M | -$50.02M | $178.79M | -$18.74M | -$2.45M | $1.32M | $1.32M | -$8.64M |
| Depreciation & amortization | $941,000 | $957,000 | $963,000 | $898,000 | $905,000 | $885,000 | $981,000 | $997,000 |
| Stock-based compensation | $23.08M | $11.33M | $6.93M | $8.85M | $6.91M | $5.87M | $6.40M | $5.02M |
| Share buybacks | $11.99M | $51.95M | $76.15M | $25.48M | $16.22M | $0 | $0 | $9.43M |
Free plan shows the latest 8 periods; Pro shows all 23 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.